Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma

The design of innovative, more effective, less toxic therapy of multiple myeloma (MM) is emerging in parallel to a better understanding of the underlying pathophysiology of this common hematologic malignancy. Thalidomide has changed the treatment paradigm of patients with MM. Its efficacy, however,...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecules & biomedicine 2009-10, Vol.9 Suppl 1 (1), p.S3-S10
Main Authors: Srkalovic, Gordan, Hussein, Mohamad
Format: Article
Language:English
Subjects:
Clinical Trials, Phase III as Topic
Humans
IMiDs
Immunologic Factors - therapeutic use
Lenalidomide
multiple myeloma
Multiple Myeloma - drug therapy
pomalidomide
thalidomide
Thalidomide - analogs & derivatives
Thalidomide - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The design of innovative, more effective, less toxic therapy of multiple myeloma (MM) is emerging in parallel to a better understanding of the underlying pathophysiology of this common hematologic malignancy. Thalidomide has changed the treatment paradigm of patients with MM. Its efficacy, however, has been compromised by significant side effects. IMiDs (immunodulatory compounds) are structural and functional analogs of thalidomide that were specifically designed to create new agents with enhanced immunomodulatory and anticancer properties and better tolerability profiles. In this article, we review the clinical trial development of the second-generation IMiDs, lenalidomide and pomalidomide. Both agents demonstrate potent activity and are highly effective and well tolerated treatment options for patients with MM.
ISSN:1512-8601
2831-0896
1840-4812
2831-090X
DOI:10.17305/bjbms.2009.2747